Phenazopyridine

A urinary tract analgesic dye that relieves burning, urgency and pain from irritated lower urinary tract lining; sold by prescription and over the counter.

psilodex.org/m/phenazopyridine · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: Not stated in label or references

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Phenazopyridine”, v2026.10.05. psilodex.org/m/phenazopyridine

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

Sold without FDA approval

Prescription phenazopyridine is marketed without FDA approval (DailyMed marketing category: unapproved drug other); lower-strength products are sold over the counter.

Sources [1]

Other safety

The label reports methemoglobinemia, hemolytic anemia, and kidney and liver toxicity, usually at overdose levels; it is contraindicated in kidney insufficiency.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin, and no mechanism linking them has been described. Separately, it turns urine reddish-orange.

Human data with psilocybin: No psilocybin data; based on its label

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Phenazopyridine hydrochloride tablets (Genus Lifesciences) · FDA label (DailyMed) — revised 2026-07 | Indications "Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa" | Adverse Reactions "Methemoglobinemia, hemolytic anemia, renal and hepatic toxicity have been reported, usually at overdosage levels" | SPL marketing category "Unapproved drug other"
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →